Details of the Drug Reposition

General Information of This Drug (ID: DM574C8)

Drug Name
Rintatolimid   DM574C8
Synonyms
Ampligen; Atvogen; Poly I:Poly C12U; POLYI-POLYC12U; Poly(I).poly(c12,U); Mismatched double-stranded RNA; Poly I-Poly C (C12,U); (rI(n).r(C(12)U)n); DRG-0001; Poly(inosinic acid) poly(cytidylic(12), uridylic)acid; 38640-92-5; 5'-Inosinic acid, homopolymer, complex with 5'-cytidylic acid polymer with 5'-uridylic acid (1:1); Poly(I)-Poly(C12U); Rintatolimod [USAN:INN]; UNII-94325AJ25N; SCHEMBL27306; AC1L1Z15; DTXSID50191952; 94325AJ25N; LS-174734; C10H13N4O8P.C9H13N2O9P.C9H14N3O8P; 1308845-87-5; 1221495-86-8
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1/2 [1]
------------------------------------------------------------------------------------
1 Application submitted Indication(s)
Indication Name Indication ID ICD-11 Status REF
Chronic fatigue syndrome DIS34WJ5 8E49 Application submitted [2]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)